Vanessa Malier (L) and Rémi Droller, managing partners at Kurma Partners
March 8, 2022 10:38 AM ESTUpdated 03:29 PM
Financing

Kur­ma scores $175M in first clos­ing of biotech/healthtech fund — the VC's largest yet

Paul Schloesser

Associate Editor

French VC Kur­ma has been in­vest­ing in­to sev­er­al com­pa­nies re­cent­ly, such as AR­M­GO Phar­ma and Emer­gence Ther­a­peu­tics. With its new biotech and healthtech-fo­cused fund, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times